Table 2. Patients with definitive... | American Society of Hematology

Table 2.

Patients with definitive evidence of an IGL-λ translocation in MGUS

No.	Translocation	V_λ/C_λsegregation strategy	Fusion assay (abnormal cells), %	Cyclin D1	Δ13 assay	Heavy chain	Light chain	BM PCs, %	Follow-up since diagnosis, mo	Follow-up since translocation detection, mo	Fusion assay (abnormal cells), %
No.	Translocation	V_λ/C_λsegregation strategy	Fusion assay (abnormal cells), %	Cyclin D1	deleted/ normal	%	Light chain	BM PCs, %	Follow-up since diagnosis, mo	Follow-up since translocation detection, mo	Fusion assay (abnormal cells), %
28	IgL-λ	37	ND	ND	−	8	G	κ	7.0	10.7	11.0
29	IgL-λ	89	ND	ND	+	98	G	κ	29.6	46.7	3.2
30	IgL-λ	90	ND	ND	ND	ND	A	κ	2.0	0.2	0.2

No.	Translocation	V_λ/C_λsegregation strategy	Fusion assay (abnormal cells), %	Cyclin D1	Δ13 assay	Heavy chain	Light chain	BM PCs, %	Follow-up since diagnosis, mo	Follow-up since translocation detection, mo	Fusion assay (abnormal cells), %
No.	Translocation	V_λ/C_λsegregation strategy	Fusion assay (abnormal cells), %	Cyclin D1	deleted/ normal	%	Light chain	BM PCs, %	Follow-up since diagnosis, mo	Follow-up since translocation detection, mo	Fusion assay (abnormal cells), %
28	IgL-λ	37	ND	ND	−	8	G	κ	7.0	10.7	11.0
29	IgL-λ	89	ND	ND	+	98	G	κ	29.6	46.7	3.2
30	IgL-λ	90	ND	ND	ND	ND	A	κ	2.0	0.2	0.2

− indicates normal; +, deleted; ND, not done.